ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

NEXT STORY
Antares Pharma Announces Partner Idorsia Initiates the Phase 3 Study With Selatogrel for Acute Myocardial Infarction
PREV STORY
Psyence Group Announces Appointment of New Chief Executive Officer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer

-PyL highly sensitive, 93-99%, in reliably detecting metastatic prostate cancer lesions and highly specific, 96-99%, ...

author_avatar
NASDAQ Market News

UroGen Pharma Welcomes New Board Member Kate Falberg

RA’ANANA, Israel, April 24, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a privately held, ...

author_avatar
NASDAQ Market News

Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases

European Commission's (EC) approval based on comprehensive data package confirming that Zessly® matches safety, ...

author_avatar
NASDAQ Market News